This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
Drug Development

Catabasis pursues bifunctional mutation-agnostic approach to DMD

Posted by on 14 July 2017
Share this article

Using its safely metabolized and rationally targeted (SMART) linker platform, Catabasis has identified an NF-κB inhibitor—edasalonexent—as a potential Duchenne muscular dystrophy (DMD) treatment. Speaking at the 2017 Biotech Showcase, Dr. Jill Milne, co-founder, president and CEO of Catabasis, describes to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, the company’s ambitions to pursue a pivotal Phase III trial this year.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Jill C. Milne – President and CEO, Catabasis

Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down